NCT05872243Completed
pBFS Guided rTMS Treating Mild Alzheimer's Disease(AD)
A Prospective, Randomized, Double-blind, Controlled Trial of rTMS in the Treatment of Mild Alzheimer's Disease Guided by Personalized Brain Functional Sectors(pBFS)
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
This study aims to investigate the effectiveness and safety of rTMS treatment under the guidance of personalized Brain Functional Sectors (pBFS) for the cognitive ability of patients with mild Alzheimer's disease.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 46 (actual)
- First submitted
- 14 May 2023
- Start date
- 5 Sept 2023
- Primary completion date
- 13 Dec 2024
- Lead sponsor
- Changping Laboratory
- Diseases
- Alzheimer disease
- NCT number
- NCT05872243
What you commit to
- Study type: Interventional
- Participants enrolled: 46
- From 5 Sept 2023 to the primary completion date, 13 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with acute cardiovascular and cerebrovascular events within the 3 months prior to screening.
- Having received other TMS treatments within the past three months.
Other illness
- Patients who have other causes of cognitive decline apart from AD, including but not limited to vascular dementia, Parkinson's disease dementia, dementia with Lewy bodies, frontotemporal dementia, and dementia due to endocrine system lesions or deficiencies of folic acid, vitamin B12 or other causes.
- Patients with a history of seizures or epilepsy syndrome, or seizures within the past 12 months.
- Patients with severe cardiac, pulmonary, hepatic, renal, and other systemic diseases that cannot be controlled with conventional medications.
- Patients with malignant tumors or a life expectancy of less than 1 year due to reasons other than AD.
- History of alcohol or drug abuse.
Other
- Patients with significant focal lesions seen on MRI, including more than two infarct foci larger than 2 cm in diameter, infarct foci in key areas such as the thalamus, hippocampus, internal olfactory cortex, pars oligo-cortical, angular gyrus, cortical and other subcortical gray matter nuclei.
- Patients with moderate to severe cerebral white matter degeneration ( Fazekas score of 3-6).
- Patients unable to undergo TMS treatment or MRI scan due to metallic foreign bodies, implanted electronic devices, or claustrophobia.
- Having participated, or is currently participating in other clinical trial programs within the past three months.
Who the study is looking for
- Diagnosis of probable Alzheimer's disease (probable AD) based on the AD diagnostic criteria proposed by NIA-AA.
- Positive PET or positive cerebrospinal fluid test results for beta-amyloid (Aβ).
- Elementary school education or higher.
- MMSE scores between 20 and 26 (including 20 and 26), or 18 and 26 for those with elementary school education.
- Clinical Dementia Scale (CDR) score of 1, indicating mild dementia.
- Stable medication for Alzheimer's disease for at least 3 months prior to treatment.
- Availability of a reliable caregiver who can assist and accompany the patient throughout the study.
- Voluntary participation with signed informed consent by the patient or legal guardian.
Age in the registry: 50 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xuanwu Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.